About Acetylon
Acetylon is a Healthcare company based in Boston (United States) founded in 2008 by Marc Cohen, and was acquired by Celgene in December 2016. Next-generation selective HDAC inhibitors are developed for multiple diseases. Acetylon has raised $138.24 million across 6 funding rounds from investors including HHS, Celgene and The Kraft Group. The company has 37 employees. Its chief executive, as recorded, is Mark Alles. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ACETYLON PHARMACEUTICALS INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Acetylon Pharmaceuticals, Inc. intends to manufacture small molecule drugs to realize the therapeutic potential of histone deacetylase. The company is pursuing development of next-generation, selective histone deacetylase (HDAC) enzyme inhibitors with potential for treatment of hematologic and solid tumor cancers, inflammatory diseases such as rheumatoid arthritis, neurodegenerative diseases such as Parkinsons, genetic diseases incluidng sickle cell disease and thalassemia major, and infectious disease such as malaria. Acetylons technology is being licensed from Harvard University and the Dana Farber Cancer Center. Acetylons lead drug candidate, ricolinostat (ACY-1215), is currently in clinical trials for the treatment of multiple myeloma and lymphoma.
- Headquarters Boston, United States
- Employees 37
- Founders Marc Cohen
- Stage Acquired
- SectorsHealthcare
- Website acetylon.com
- Social LinkedIn
- Acquired by Celgene (Dec 2016)
- Legal Name Acetylon Pharmaceuticals Inc
Funding Insights of Acetylon
Acetylon has successfully raised a total of $138.24M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $367.97 thousand completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $138.24M
- Total Rounds 6
- Last Round Grant — $367,972
- First Round $7.25M
(Aug 2009)
- Investors Count 3
All 6 funding rounds of Acetylon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2013 | $367,972 | Grant | – | – | |
| Jul 2013 | $100M | Series B | – | Celgene | – |
| Feb 2012 | $15M | Series B | – | Celgene | – |
| Aug 2011 | $13.99M | Series B | – | – | – |
| Jan 2010 | $2M | Series A | – | – | – |
| Aug 2009 | $7.25M | Series A | – | The Kraft Group | – |
3 investors in total: 3 institutional.
Investors in Acetylon
Acetylon has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Celgene and The Kraft Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments and family assets are managed by The Kraft Group. | thekraftgroup.com | Foxborough, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Acetylon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acetylon
2 people are tracked at Acetylon (2 in leadership); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Marc Cohen | Co-Founder | Leadership |
Mark Alles | Chairman & CEO | Leadership |
Complete people profiles for Acetylon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acetylon
4 dated milestones of Acetylon across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Acetylon is founded.
- Funding First funding round of $7.2M.
- Funding Latest funding round, Grant, of $368K.
- Exit Acquired by Celgene.
Competitors of Acetylon
Acetylon has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Acetylon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acetylon
Websites that share an audience with Acetylon (acetylon.com).
Websites whose visitors overlap most with Acetylon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Oncology
3 companies that operate in the same segment as Acetylon (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acetylon
Acetylon was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Acetylon is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Mark Alles is the CEO of Acetylon, as recorded in our data.
Acetylon is a funded company, having raised a total of $138.24M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7.25M, raised on Aug 2009.
Acetylon has 37 employees.
Acetylon Pharmaceuticals, Inc. intends to manufacture small molecule drugs to realize the therapeutic potential of histone deacetylase. The company is pursuing development of next-generation, selective histone deacetylase (HDAC) enzyme inhibitors with potential for treatment of hematologic and solid tumor cancers, inflammatory diseases such as rheumatoid arthritis, neurodegenerative diseases such as Parkinsons, genetic diseases incluidng sickle cell disease and thalassemia major, and infectious disease such as malaria. Acetylons technology is being licensed from Harvard University and the Dana Farber Cancer Center. Acetylons lead drug candidate, ricolinostat (ACY-1215), is currently in clinical trials for the treatment of multiple myeloma and lymphoma.
Acetylon has 3 investors. Key investors include HHS, Celgene, and The Kraft Group.
Acetylon operates through Acetylon Pharmaceuticals Inc.
Yes. Acetylon was acquired by Celgene in December 2016.